Cargando…

Hemostatic phenotypes and genetic disorders

This review is focused on genetic regulators of bleeding and thrombosis with a focus on next‐generation sequencing (NGS) technologies for diagnosis and research of patients with inherited disorders. The molecular diagnosis of hemostatic phenotypes relies on the detection of genetic variants in the 9...

Descripción completa

Detalles Bibliográficos
Autores principales: Ver Donck, Fabienne, Labarque, Veerle, Freson, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677882/
https://www.ncbi.nlm.nih.gov/pubmed/34964017
http://dx.doi.org/10.1002/rth2.12637
_version_ 1784616234260627456
author Ver Donck, Fabienne
Labarque, Veerle
Freson, Kathleen
author_facet Ver Donck, Fabienne
Labarque, Veerle
Freson, Kathleen
author_sort Ver Donck, Fabienne
collection PubMed
description This review is focused on genetic regulators of bleeding and thrombosis with a focus on next‐generation sequencing (NGS) technologies for diagnosis and research of patients with inherited disorders. The molecular diagnosis of hemostatic phenotypes relies on the detection of genetic variants in the 99 curated disease‐causing genes implicated for bleeding, platelet, and thrombotic disorders through the use of multigene panel tests. In this review, we will provide an overview of the advantages and disadvantages of using such multigene panel tests for diagnostics. During the past decade, NGS technologies have also been used for the gene discovery of 32 novel genes involved in inherited hemostatic phenotypes. We will provide a brief overview of these genes and discuss what information (eg, linkage, consanguinity, multiple index cases with similar phenotypes, mouse models, and more) was used to support the gene discovery process. Next, we provide examples on how RNA sequencing is useful to explore disease mechanisms of novel and often unexpected genes. This review will summarize the important findings concerning NGS technologies for diagnostics and gene discovery that were presented at the ISTH 2021 conference. Finally, future perspectives in our field mainly deal with finding the needle in the haystack for some still unexplained patients and the need for exploring the noncoding gene space and rapid disease validation models.
format Online
Article
Text
id pubmed-8677882
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86778822021-12-27 Hemostatic phenotypes and genetic disorders Ver Donck, Fabienne Labarque, Veerle Freson, Kathleen Res Pract Thromb Haemost State of the Art Isth 2021 This review is focused on genetic regulators of bleeding and thrombosis with a focus on next‐generation sequencing (NGS) technologies for diagnosis and research of patients with inherited disorders. The molecular diagnosis of hemostatic phenotypes relies on the detection of genetic variants in the 99 curated disease‐causing genes implicated for bleeding, platelet, and thrombotic disorders through the use of multigene panel tests. In this review, we will provide an overview of the advantages and disadvantages of using such multigene panel tests for diagnostics. During the past decade, NGS technologies have also been used for the gene discovery of 32 novel genes involved in inherited hemostatic phenotypes. We will provide a brief overview of these genes and discuss what information (eg, linkage, consanguinity, multiple index cases with similar phenotypes, mouse models, and more) was used to support the gene discovery process. Next, we provide examples on how RNA sequencing is useful to explore disease mechanisms of novel and often unexpected genes. This review will summarize the important findings concerning NGS technologies for diagnostics and gene discovery that were presented at the ISTH 2021 conference. Finally, future perspectives in our field mainly deal with finding the needle in the haystack for some still unexplained patients and the need for exploring the noncoding gene space and rapid disease validation models. John Wiley and Sons Inc. 2021-12-16 /pmc/articles/PMC8677882/ /pubmed/34964017 http://dx.doi.org/10.1002/rth2.12637 Text en © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle State of the Art Isth 2021
Ver Donck, Fabienne
Labarque, Veerle
Freson, Kathleen
Hemostatic phenotypes and genetic disorders
title Hemostatic phenotypes and genetic disorders
title_full Hemostatic phenotypes and genetic disorders
title_fullStr Hemostatic phenotypes and genetic disorders
title_full_unstemmed Hemostatic phenotypes and genetic disorders
title_short Hemostatic phenotypes and genetic disorders
title_sort hemostatic phenotypes and genetic disorders
topic State of the Art Isth 2021
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677882/
https://www.ncbi.nlm.nih.gov/pubmed/34964017
http://dx.doi.org/10.1002/rth2.12637
work_keys_str_mv AT verdonckfabienne hemostaticphenotypesandgeneticdisorders
AT labarqueveerle hemostaticphenotypesandgeneticdisorders
AT fresonkathleen hemostaticphenotypesandgeneticdisorders